Probiotics and the Gut Brain Axis- Do Probiotics Interact With the Vagal Nerve?

NCT ID: NCT04772664

Last Updated: 2024-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-16

Study Completion Date

2023-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effects of a multispecies probiotic on the function of the vagal nerve in patients with major depression and healthy participants in a single-center, randomized, placebo-controlled trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After being informed about the study and potential risks, all participants giving written informed consent will be screened for eligibility for study entry and will be randomized in a double-blind manner to receive either a multistrain probiotic or a placebo for 3 months. At entry, 1 week after inclusion, 4 weeks after inclusion and 3 months (end of study) vagal activity will be measured using a 24hr electrocardiogram.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Major Depression receiving a multi-strain probiotic

Participants with Major Depression receiving a multi-strain probiotic

Group Type EXPERIMENTAL

Multispecies-Probiotic

Intervention Type DIETARY_SUPPLEMENT

Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.

Participants mit Major Depression receiving a placebo

Participants mit Major Depression receiving a placebo

Group Type PLACEBO_COMPARATOR

Placebo Supplement

Intervention Type DIETARY_SUPPLEMENT

Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.

Healthy volunteers receiving a multi-strain probiotic

Healthy volunteers receiving a multi-strain probiotic

Group Type EXPERIMENTAL

Multispecies-Probiotic

Intervention Type DIETARY_SUPPLEMENT

Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.

Healthy volunteers receiving a placebo

Healthy volunteers receiving a placebo

Group Type PLACEBO_COMPARATOR

Placebo Supplement

Intervention Type DIETARY_SUPPLEMENT

Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multispecies-Probiotic

Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.

Intervention Type DIETARY_SUPPLEMENT

Placebo Supplement

Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Omnibiotic-SR Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* informed consenct
* confirmed diagnosis of depression according to ICD-10 or DSM-V
* age between 18 and 65 years

Exclusion Criteria

* Suicidality
* no informed consent or no ability to provide consent
* cardiovascular disease
* pregnancy, breastfeeding
* alcohol or drug dependency
* other severe psychiatric or organic conditions (epilepsy, brain tumor, recent surgery)
* malignant diseases
* dementia (MMST\<20)
* severe autoimmune-disorder or immunosuppression (systemic lupus, HIV, multiple sclerosis)
* antibiotic therapy in the last month
* misuse of laxative
* acute infections
* diarrhoea
* gastrointestinal surgeries (except appendectomy)
* no probiotic intake in the last 6 months
* no regular intake of other supplements, probiotics or antibiotics during the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergosan

UNKNOWN

Sponsor Role collaborator

Medical University of Graz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of Graz

Graz, Styria, Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK1019/2021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.